AB&B Bio-Tech Co. Ltd. JS said the U.S. Food and Drug Administration has approved its Investigational New Drug application for a self-developed mRNA mpox vaccine candidate, allowing the program to proceed to clinical development in the United States. The company stated this is China’s first and the world’s third mRNA mpox vaccine candidate to receive FDA IND approval.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AB&B Bio-Tech Co. Ltd. JS published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260304-12039863), on March 04, 2026, and is solely responsible for the information contained therein.